CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

被引：2

作者：

Storci, Gianluca ^{[1
]}

De Felice, Francesco ^{[1
,2
]}

Ricci, Francesca ^{[1
]}

Santi, Spartaco ^{[3
,4
]}

Messelodi, Daria ^{[1
]}

Bertuccio, Salvatore Nicola ^{[1
]}

Laprovitera, Noemi ^{[1
]}

Dicataldo, Michele ^{[1
,2
]}

Rossini, Lucrezia ^{[2
]}

De Matteis, Serena ^{[1
]}

Casadei, Beatrice ^{[1
]}

Vaglio, Francesca ^{[1
]}

Ursi, Margherita ^{[1
,2
]}

Barbato, Francesco ^{[1
,2
]}

Roberto, Marcello ^{[1
,2
]}

Guarino, Maria ^{[1
]}

Asioli, Gian Maria ^{[1
]}

Arpinati, Mario ^{[1
]}

Cortelli, Pietro ^{[5
,6
]}

Maffini, Enrico ^{[1
]}

Tomassini, Enrica ^{[1
]}

Tassoni, Marta ^{[2
]}

Cavallo, Carola ^{[7
]}

Iannotta, Francesco ^{[1
]}

Naddeo, Maria ^{[1
,2
]}

Tazzari, Pier Luigi ^{[1
]}

Dan, Elisa ^{[1
]}

Pellegrini, Cinzia ^{[1
]}

Guadagnuolo, Serafina ^{[1
]}

Carella, Matteo ^{[1
,2
]}

Sinigaglia, Barbara ^{[1
]}

Pirazzini, Chiara ^{[2
]}

Severi, Caterina ^{[8
]}

Garagnani, Paolo ^{[1
,2
]}

Kwiatkowska, Katarzyna Malgorzata ^{[2
]}

Ferracin, Manuela ^{[1
,2
]}

Zinzani, Pier Luigi ^{[2
,9
]}

Bonafe, Massimiliano ^{[1
,2
]}

Bonifazi, Francesca ^{[1
]}

机构：

[1] IRCCS, Azienda Osped Univ Bologna, Bologna, Italy

[2] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[3] IRCCS, Ist Ortoped Rizzoli, Bologna, Italy

[4] Natl Res Council Italy, Inst Mol Genet, Bologna, Italy

[5] Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Bologna, Italy

[6] IRCCS, Bellaria Hosp, Inst Neurol Sci Bologna, Bologna, Italy

[7] IRCCS, Res & Innovat Technol Dept, Ist Ortoped Rizzoli, Lab Ramses, Bologna, Italy

[8] Abbelight, Cachan, France

[9] IRCCS, Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2024年 / 134卷 / 14期

关键词：

THERAPY; NEUROTOXICITY; MANAGEMENT; CHILDREN; ADULTS; BLOOD;

D O I：

10.1172/JCI173096

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

BACKGROUND. Predicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises a few days after infusion, when circulating CAR T cells are scarce and specific CAR T cell-derived biomarkers are lacking. METHODS. CAR + extracellular vesicle (CAR + EV) release was assessed in human CD19.CAR T cells cocultured with CD19 + target cells. A prospective cohort of 100 patients with B cell lymphoma infused with approved CD19.CAR T cell products was assessed for plasma CAR + EVs as biomarkers of in vivo CD19.CAR T cell activation. Human induced pluripotent stem cell- derived (iPSC-derived) neural cells were used as a model for CAR + EV-induced neurotoxicity. RESULTS. In vitro release of CAR + EVs occurs within 1 hour after target engagement. Plasma CAR + EVs are detectable 1 hour after infusion. A concentration greater than 132.8 CAR + EVs/ mu L at hour +1 or greater than 224.5 CAR + EVs/ mu L at day +1 predicted ICANS in advance of 4 days, with a sensitivity and a specificity outperforming other ICANS predictors. ENO2 + nanoparticles were released by iPSC-derived neural cells upon CAR + EV exposure and were increased in plasma of patients with ICANS. CONCLUSION. Plasma CAR + EVs are an immediate signal of CD19.CAR T cell activation, are suitable predictors of neurotoxicity, and may be involved in ICANS pathogenesis.

引用

页数：17

共 50 条

[21] Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
Hashmi, Hamza
Mirza, Abu-Sayeef
Darwin, Alicia
Logothetis, Constantine
Garcia, Franco
Kommalapati, Anuhya
Mhaskar, Rahul S.
Bachmeier, Christina
Chavez, Julio C.
Shah, Bijal
Pinilla-Ibarz, Javier
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien
Davila, Marco L.
Locke, Frederick L.
Nishihori, Taiga
Jain, Michael D.
BLOOD ADVANCES, 2020, 4 (17) : 4086 - 4090
[22] Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency
Salloum, Darin
Tundwal, Kavita
Choi, Kwang Bom
Ranere, Ashley
Lock, Jaclyn
Lam, Ben
Kristianto, Jasmin
Yu, John
Li, Jessica
Lam, John
Beauchesne, Pascal
O'Rourke, Allison
Liang, Ouwen
Lampano, Aaron
van Hoeven, Neal
Kouros-Mehr, Hosein
Shivak, Dave
Zhang, Weidong
Wan, Tiffany
Arjes, Lisa
Chaivorapol, Christina
Wong, Athena
Johnson, Adam
Brunetta, Paul
Fry, Terry
BLOOD, 2023, 142
[23] Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy
Karmali, Reem
Shouse, Geoffrey
Torka, Pallawi
Moyo, Tamara K.
Romancik, Jason
Barta, Stefan K.
Bhansali, Rahul
Cohen, Jonathon B.
Shah, Nirav N.
Zurko, Joanna
Kenkre, Vaishalee P.
Hess, Brian
Stephens, Deborah M.
Fitzgerald, Lindsey
Ollila, Thomas
Tabiti, Bukky
Roy, Ishan
Ma, Shuo
Winter, Jane
Pro, Barbara
Moreira, Jonathan
Danilov, Alexey V.
David, Kevin
Gordon, Leo I.
Epperla, Narendranath
BLOOD CANCER JOURNAL, 2025, 15 (01):
[24] The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+B-ALL
Hong, Zhenya
Yang, Zhi
Zhou, Xiaoxi
Wang, Gaoxiang
Zhou, Mi
Zhang, Yingzi
Zhang, Peiling
Huang, Jinjin
Meng, Li
Ruan, Haitao
Xiao, Min
Li, Yunyan
Wang, Linling
Wang, Meiling
Zhu, Wei
Zhang, Qianzhen
Shen, Junjie
Zhou, Jianfeng
Qian, Cheng
Huang, Liang
BLOOD, 2022, 140 : 4625 - 4626
[25] Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
Zurko, Joanna
Shouse, Geoffrey
Torka, Pallawi
Moyo, Tamara K.
Romancik, Jason T.
Nizamuddin, Imran A.
Annunzio, Kaitlin
Liu, Jieqi
Barta, Stefan K.
Ferdman, Robert
Bhansali, Rahul
Cohen, Jonathon B.
Chowdhury, Sayan Mullick
Shah, Nirav N.
Harris, Elyse, I
Kenkre, Vaishalee P.
Sorrell, McKenzie
Hess, Brian T.
Stephens, Deborah M.
Fitzgerald, Lindsey A.
Ollila, Thomas A.
Roy, Ishan
Ma, Shuo
Winter, Jane N.
Pro, Barbara
Moreira, Jonathan
Gordon, Leo, I
Danilov, Alexey, V
Evens, Andrew M.
Epperla, Narendranath
Karmali, Reem
BLOOD, 2022, 140
[26] CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)
Baird, John H.
Del Real, Marissa Morales
Song, Joo Y.
Shouse, Geoffrey P.
Danilov, Alexey
Herrera, Alex F.
Popplewell, Leslie L.
Rosen, Steven T.
Davis, Jennifer
Barva, Baishakhi
Chen, Lu
Kwak, Larry W.
Forman, Stephen J.
Budde, L. Elizabeth
BLOOD, 2023, 142
[27] Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
Domizi, Pablo
Jager, Astraea
Sarno, Jolanda
Mullighan, Charles G.
Grupp, Stephan
Sotillo, Elena
Barrett, David M.
Davis, Kara L.
BLOOD, 2019, 134
[28] Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy
Samantha El Warrak
Mohamed A. Kharfan-Dabaja
Madiha Iqbal
Mehdi Hamadani
Julio Chavez
Razan Mohty
Bone Marrow Transplantation, 2024, 59 : 162 - 170
[29] Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells
Uy, Natalie F.
Pequignot, Edward
Frey, Noelle V.
Davis, Megan
Hexner, Elizabeth O.
Schuster, Stephen J.
Gill, Saar
Loren, Alison W.
Grupp, Stephan A.
Melenhorst, J. Joseph
Lacey, Simon F.
Fraietta, Joseph A.
Gilmore, Joan
Lledo, Lester
Hwang, Wei-Ting
Siegel, Don L.
Levine, Bruce L.
June, Carl H.
Porter, David L.
BLOOD, 2020, 136
[30] Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy
El Warrak, Samantha
Kharfan-Dabaja, Mohamed A.
Iqbal, Madiha
Hamadani, Mehdi
Chavez, Julio
Mohty, Razan
BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 162 - 170

← 1 2 3 4 5 →